Development of alloantibodies to the initial donor's platelets and/or lymphocytes
. | No. antibody-positive/no. tested . | . | |
|---|---|---|---|
| Transfusion group . | Refractory recipients . | Accepting recipients . | |
| Standard | 6/6 | — | |
| Single treatment | |||
| F-LR × 1 | 2/2 | 2/2 | |
| F-LR × 2 | 4/4 | 0/1 | |
| Combined treatment | |||
| F-LR/C-LR | 2/2 | 3/13 | |
| γ-F-LR/C-LR | — | 0/6 | |
. | No. antibody-positive/no. tested . | . | |
|---|---|---|---|
| Transfusion group . | Refractory recipients . | Accepting recipients . | |
| Standard | 6/6 | — | |
| Single treatment | |||
| F-LR × 1 | 2/2 | 2/2 | |
| F-LR × 2 | 4/4 | 0/1 | |
| Combined treatment | |||
| F-LR/C-LR | 2/2 | 3/13 | |
| γ-F-LR/C-LR | — | 0/6 | |
Results are reported for dogs who had all 3 antibody tests run with the initial donor's platelets and lymphocytes. A positive result indicates that the recipient serum reacted with the donor's platelets and/or lymphocytes in at least 1 assay with 2 sequential weekly serum samples.
— indicates not applicable.